TGFB1 and atrial fibrillation: A wide range of potential drugs with anti‐fibrotic effects reduce atrial interstitial fibrosis and AF in experimental studies, albeit at various targets, including TGF‐β, inflammatory mediators and fibroblast‐associated proteins.